When was CG Oncology founded?

CG Oncology was founded in 2010 and raised its 1st funding round 4 years after it was founded.

Where is CG Oncology located?

CG Oncology is headquartered in Irvine, United States. It is registered at 400 Spectrum Center Drive Suite #2040 Irvine, CA 92618.

How many employees does CG Oncology have?

As of Jul 31, 2026, the latest employee count at CG Oncology is 193.

Is CG Oncology a funded company?

CG Oncology is a funded company, having raised a total of $318M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 30, 2014.

When was the latest funding round of CG Oncology?

CG Oncology's latest funding was a $***** Series E round on Aug 01, 2023, with participation from 10 investors.

What is the annual revenue of CG Oncology?

Annual revenue of CG Oncology is between $1M and $10M as on Dec 31, 2025

Where does CG Oncology rank among its competitors?

CG Oncology ranks 52nd amongst 3359 active competitors, of which 1145 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of CG Oncology?

CG Oncology's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

CG Oncology - 2026 Company Profile, Team, Funding, Competitors & Financials

CG Oncology is a public company based in Irvine (United States), founded in 2010. It operates as a Developer of immunotherapeutic agents for treating cancer. CG Oncology has raised $318M in funding from investors like ORI Capital, Longitude Capital and Decheng Capital. The company has 3359 active competitors, including 1145 funded and 800 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

GC Oncology develops immunotherapeutic agents for treating cancer. The agents CG0070 is a modified adenovirus type 5 (Ad5) carrying an E2F-1 promoter upstream of an E1A promoter, and the gene for GM-CSF. The modification enables the virus to selectively target and replicate in cancer cells. The T cells are then able to circulate throughout the body, recognizing and attacking residual cancer.

Website: cgoncology.com
Social
Email ID: *****@cgoncology.com
Registered Address: 400 Spectrum Center Drive Suite #2040 Irvine, CA 92618

Key Metrics

Founded Year

2010

Location

Irvine, United States

Stage

Public

Total Funding

$318M in 6 rounds

Latest Funding Round

Series E, Aug 01, 2023, $*****

Investors

ORI Capital & 17 more

Ranked

52^nd among 3359 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

193 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3136 more

Exit Details

Public

View CG Oncology's full profile

CG Oncology is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cg Oncology, Inc. CIN: - , United States, Active	Nov 29, 2017	$1M - $10M (As on Dec 31, 2025)	-	-

CG Oncology got listed on Jan 25, 2024.

Click here to take a look at CG Oncology's IPO in detail

CG Oncology has raised a total funding of $318M over 6 rounds. Its first funding round was on Jul 30, 2014. Its latest funding round was a Series E round on Aug 01, 2023 for $*****. 10 investors participated in its latest round. CG Oncology has 18 institutional investors.

Here is the list of recent funding rounds of CG Oncology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2023	7718626	Series E	1451888	1326893	1214112	4045079
Nov 15, 2022	3897259	Series E	5433528	4951728	6919172	RA Capital Management & 3 more
Dec 10, 2020	9810059	Series D	4076707	4169642	Kissei Pharmaceutical	ORI Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of CG Oncology's funding rounds and investors

CG Oncology's employee count trend

CG Oncology has 193 employees as of Jul 26. Here is CG Oncology's employee count trend over the years:

Uncover CG Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CG Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of CG Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
52nd	CG Oncology 2010, Irvine (United States), Public	Developer of immunotherapeutic agents for treating cancer	$318M	Foresite Capital, BVF Partners & 16 others	65/100